All In Biotech

Drug Trial Radar · NCT05012423

FTIH Study of ECC0509 in Healthy Volunteers

A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose, First-Time-In-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ecc0509 in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Sep 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

89

Actual

Start

Jul 26, 2021

Primary completion

Jul 22, 2023

Study completion Jul 22, 2023

Sponsor

Lead sponsor
EccogeneIndustry
Sponsor type
Industry
First posted
Aug 19, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single And Multiple Ascending Dose, First-Time-In-Human Study to Assess The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ECC0509 in Healthy Volunteers.

Conditions

  • Nonalcoholic Steatohepatitis
  • Osteoarthritis

Interventions

  • PlaceboDrug

    Matching Placebo will be administered as oral capsules.

  • ECC0509Drug

    ECC0509 1 mg and 10 mg capsules. ECC0509 will be administered as oral capsules.

  • PlaceboDrug

    Matching Placebo will be given orally during each dosing day.

  • ECC0509Drug

    ECC0509 1 mg and 10 mg capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events, with abnormal laboratory test results, abnormal ECGs, abnormal vital signs, and abnormal physical examinationsTime frame: SAD: Up to Day 8. MAD: Up to Day 21.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CMAX Clinical Research

    Adelaide, South Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.